Italy, Germany, France and Netherlands sign contract with Astrazeneca for COVID-19 vaccine

2 | Next crop of COVID-19 vaccine developers take more traditional route: The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs. The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop. Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed.

Italy, Germany, France and the Netherlands have signed a contract with Astrazeneca to supply European citizens with a vaccine against the coronavirus, Italy's health minister said on Saturday.

The contract is for 400 million doses of the vaccine, which was developed with the University of Oxford and whose experimentation phase is already advanced and expected to end in autumn, Roberto Speranza said in a Facebook post.

He added that a first batch of doses would be made available by the end of this year.

The European Commission received a mandate from EU governments on Friday to negotiate advance purchases of promising coronavirus vaccines, the EU's top health official said, but it was unclear whether there would be enough money available.

Follow our full coverage of the coronavirus pandemic here.